Canaccord Maintains Buy Rating and $28 PT on AVEO Pharmaceuticals

A report from Canaccord reiterates its Buy rating and $28 price target on AVEO Pharmaceuticals AVEO. The report states, “Ahead of a December 7 ODAC meeting to discuss the merits of the NDA for Pfizer's axitinib, a potential competitor to AVEO's tivozanib in advanced renal cell carcinoma (RCC), we maintain our BUY rating on AVEO.” AVEO closed Friday at $14.99.